Nymox Pharmaceutical

Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. Its products include NicAlert and TobacAlert, and the NX-1207 for the treatment of low-grade localized prostate cancer. It operates through the following geographical segments: Canada, United States, and Europe. The company was founded by Paul Averback on May 30, 1995 and is headquartered in Nassau, the Bahamas.

Earnings data Q1 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. Its products include NicAlert, TobacAlert and Fexapotide Triflutate for the treatment of low-grade localized prostate cancer. It operates through the following geographical segments: Canada, United States, and Europe. The company was founded by Paul Averback on May 30, 1995 and is headquartered in Nassau, the Bahamas.

IRVINE, Calif., March 18, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced it has entered into definitive agreements with institutional and accredited investors for the purchase and sale of 3,030,304 common shares at a purchase price of $1.65 per share in a registered direct offering for gross proceeds of approximately $5 million before deducting placement agent fees and expenses. The Company has also agreed to issue to the investors, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of 3,030,304 common shares. The warrants are exercisable immediately at an exercise price of $2.00 per share and will expire five (5) years from the date of an effective registration statement covering the shares underlying the warrants. The closing of the offering is expected to occur on or about March 22, 2022, subject to the satisfaction of customary closing conditions.

Nymox Announces $5 Million Registered Direct Offering

IRVINE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce today that it has submitted the Company's New Drug Application (NDA) to the FDA for Fexapotide Triflutate to seek marketing approval in the U.S. for Fexapotide Triflutate for the treatment of men with benign prostatic hyperplasia (BPH).

NYMOX Announces Submission of New Drug Application (NDA) to the FDA for Fexapotide Triflutate

HASBROUCK HEIGHTS, N.J., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce that it has completed all the Company's required tasks in preparation for its planned upcoming regulatory submission for Fexapotide Triflutate for the treatment of BPH.

Nymox Shareholder Update

NYMOX Provides Current Update NYMOX Provides Current Update

NYMOX Presenting at Torrey Hills Capital Emerging Growth Conference

HASBROUCK HEIGHTS, N.J., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to provide an update on the Company's progress with its BPH treatment product Fexapotide Triflutate.

NYMOX Provides Shareholder Update

Hepion Pharmaceuticals Inc

Leap Therapeutics

Verastem

These penny stocks have upcoming events you should know about. The post 4 Biotech Penny Stocks To Watch After EFTR Stock Jumps 351% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Biotech Penny Stocks To Watch After EFTR Stock Jumps 351%

HASBROUCK HEIGHTS, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce that it will be filing for marketing approval of Fexapotide Triflutate for BPH before the end of the summer, on or before 15 September 2021.

Nymox Announces Date for Fexapotide Filing

HASBROUCK HEIGHTS, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) today announced it has entered into a definitive agreement with institutional investors in a private placement of 3,669,724 shares of common stock and warrants to purchase 1,834,862 shares of common stock at a combined purchase price of $2.18 per share for gross proceeds of approximately $8,000,000 before deducting fees and other estimated offering expenses. The warrants will have an exercise price of $2.50 per share, will be immediately exercisable and will expire five years from the date of issuance.

Nymox Announces $8,000,000 Private Placement

HASBROUCK HEIGHTS, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide the latest update on the Company's regulatory filing preparation activities. The Company expects to file for approval for its first in class BPH treatment Fexapotide Triflutate, during the summer of this year. Management will provide a firm exact date for the filing in a subsequent disclosure. This communication of the exact date for the filing will be announced by the Company within the next 6 weeks. If there are any unexpected events that delay that announcement, the Company will provide immediate relevant updates.

Nymox Provides New Update on Regulatory Activities

HASBROUCK HEIGHTS, N.J., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide a current update on the regulatory filing status for Fexapotide Triflutate (FT), Nymox's first in class lead product for the treatment of benign prostatic hyperplasia (BPH). Substantial progress has been made and there are no material changes to the content of the planned applications.

Nymox Provides Update on Regulatory Filing Activities

HASBROUCK HEIGHTS, N.J., Aug.  12, 2020  (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced it has entered into definitive agreements with institutional and accredited investors for the purchase and sale of shares of its common stock at a purchase price of $2.50 per share in a registered direct offering for gross proceeds of approximately $9 million before deducting placement agent fees and expenses. The closing of the offering is expected to occur on or about August 14, 2020, subject to the satisfaction of customary closing conditions.

Nymox Announces $9 Million Registered Direct Offering

HASBROUCK HEIGHTS, N.J., July  28, 2020  (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to report current updates on the Company's most important ongoing developments. The Company reports further significant and important progress has been made with remaining items for the upcoming regulatory filings in 2020 for the Company's first in class innovative prostate drug Fexapotide Triflutate (FT). The Company has moved swiftly ahead on its regulatory marketing applications by remote work with a strong team of expert collaborators, even with the occasional difficulties from the Covid situation leading to restricted or delayed access to certain required sources and to sites included in the Company's studies.

NYMOX Provides Current Update on Key Company Developments

HASBROUCK HEIGHTS, N.J., June  19, 2020  (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is very pleased to report that key steps in its regulatory submission preparations have been completed and the project is firmly on-track. The majority of its regulatory documentation has proceeded very well, despite the inherent limitations of the business environment in 2020. Certain tasks have been hampered by the Covid pandemic restrictions, similar to other companies in the sector. These remaining tasks are expected to be completed reasonably soon as the Company regains the ability to retrieve required documentation from external sites and to complete other required tasks and on-site activities that were hindered due to the global restrictions in place.

Nymox Announces Updates in Regulatory Submissions For Fexapotide Treatment For Prostate Enlargement

HASBROUCK HEIGHTS, N.J., April  21, 2020  (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce the recent allowances of 4 new different US and international patents concerning the Company's prostate enlargement and prostate cancer treatments. The new US and international patents that have been allowed are further expansions of Nymox's intellectual property covering the Company's prostate treatment technologies.

Nymox Announces Important New Patent Developments

HASBROUCK HEIGHTS, N.J., Feb.  24, 2020  (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce that a new peer review report was published today in the World Journal of Urology, documenting the successful long-term clinical trial results after Fexapotide Triflutate treatment for early stage prostate cancer.

Nymox Announces New Peer Review Publication of Prostate Cancer Fexapotide Clinical Trial Results in World Journal of Urology

HASBROUCK HEIGHTS, N.J., Feb.  06, 2020  (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce the new appointment of Russell I. Thomson PhD, FRSC to the position of Nymox Vice President of Quality and Regulatory Affairs.  Dr Thomson is an authority in the field of Quality Assurance and Control in the chemical and pharmaceutical industries.

Nymox Announces New Appointment of Russell Thomson Ph.D. as Nymox Vice President of Quality and Regulatory Affairs

HASBROUCK HEIGHTS, N.J., Jan.  28, 2020  (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide a current January 2020 update on several important corporate activities and achievements since the last update in October 2019.

Nymox Provides Update on Current Corporate Activities and Milestones

HASBROUCK HEIGHTS, N.J., Jan.  06, 2020  (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to report a new peer review research report has been published on experimental studies of the Company's Fexapotide Triflutate treatment for prostate enlargement (BPH) and low grade prostate cancer. The article is entitled "Fexapotide triflutate induces selective prostate glandular pharmaco-ablation in the rat" and it is published in Research and Reports in Urology.

Nymox Announces New Peer Review Article on Fexapotide Pharmaco-Ablation Experimental Studies Published in Research and Reports in Urology

HASBROUCK HEIGHTS, N.J., Oct.  21, 2019  (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to report very positive fundamental news, that the Company has received several new additional United States, European, and other jurisdictional formal patent issuances covering Fexapotide Triflutate and its use for prostate and urinary tract disorders. The effective coverage for the treatments has now been extended to 18 years into 2037 and later in the major global regions. These new patents are fully assigned to the Corporation and are the property of Nymox shareholders.

Nymox Reports on Newly Issued Patents and Corporate Developments

Carnival

Greif

Hooker Furniture

Kroger

Dave & Buster's

Insiders only buy their stocks for one reason -- to make money. Here are 6 stocks to buy based on the recent insider buying.

6 Stocks to Buy Based on Insider Buying

NYMX has been targeted by shorts like Richard Pearson, and longs have supported a completely opposite value statement.

News for Nymox Pharmaceutical Stock (NYMX)